Contact Us
Our Story
History and Milestones
Our Brand
Core Strengths
Vision, Values and Capabilities
Board of Directors
Management Team
Industry Awards and Recognition
Our Businesses
Business Portfolio
API
Domestic Formulations
International Formulations
Manufacturing
Manufacturing Facilities
Quality
Environment, Health and Safety
Scientific Overview
Research and Development
Patents
Therapeutic Focus
Nephrology
Rheumatology
Oncology
Urology
Anti-Diabetic
Respiratory
Gastroenterology
Cardiovascular
Gynaecology and Pediatrics
Vitamins and Minerals
Orthopedic
Neurology
Anti-Dengue
Dermatology
Life@RPGLS
Employee Connect
Rewards and Recognition
Brave RPGLS Covid Warriors
Great Place To Work
Team Awards
Employee Awards
Human Resources
Join Us
Company Events
Learning and Development
CSR
Corporate Social Responsibility
Explore Us
Happiness Matters!!
Investors
Financial Results
Audited Financial Results
Quarterly Financial Results
Company Presentations
Investor Presentations
Corporate Presentations
Earnings Call
Press Release
Mandatory Disclosures
Code and Policies
Shareholders Information
Shareholding Pattern
Concepts and Procedure
Corporate Governance Reports
Annual Reports
Intimation to Stock Exchange
Notices of Board Meetings
Outcome of Board Meetings
AGM & Postal Ballot
Unpaid Dividend List
TDS on Dividend Communication
Forms related to Physical Shares
Newspaper Publications
Market Tracker
Investor Relations
Investor Education and Protection Fund
Investor Grievance
Investor Contacts
Investor Meets
Committees Composition
Audit Committee
Risk Management Committee
Stakeholders Relationship Committee
Nomination & Remuneration Committee
SCSR Committee
DISCLOSURES UNDER REGULATION 46 OF LODR
Disclosures under regulation 46 of LODR
Media
Online News and Print Media
RPGLS @ Industry Platforms
PRODUCT DETAILS
Home
product details
Xecap
composition
Tab. Capecitabine IP 500mg
indications
Colorectal Cancer and Breast Cancer
Therapeutic Focus
Oncology
More
Oncology
Products
Show all
Formulation
API
Avastimab
Formulation
Bulalfa
Formulation
Hermab
Formulation
Nabpac
Formulation
Neosez
Formulation
Rivorca
Formulation
Zestmab
Formulation
Abitate
Formulation
Anarzole
Formulation
Arpimune-O
Formulation
Azaplast
Formulation
Bortemap
Formulation
Carbozar
Formulation
Chemofit
Formulation
Docel
Formulation
Emcitaben
Formulation
Erubin
Formulation
Fixpritant
Formulation
Fospritant
Formulation
Frastim
Formulation
Neomustin
Formulation
Neoxal
Formulation
Peg Frastim
Formulation
Pemexar
Formulation
Temotide
Formulation
Timinib
Formulation
Z pac
Formulation
Zubidox
Formulation
